Targets › SLC12A2
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 1; Cardiovascular, Other; next expected readout Nov 2026.
Cation-chloride cotransporter which mediates the electroneutral transport of chloride, potassium and/or sodium ions across the membrane. Plays a vital role in the regulation of ionic balance and cell volume. (UniProt, P55011)
Open in Phaseline: the race on SLC12A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Florida | Lasix ONYU Loop diuretic (furosemide) | SLC12A2 | Phase 4 | Heart Failure | Nov 2026 |
| Berlin-Chemie AG Menarini Group | Torasemide tablet 10 mg Loop diuretic - inhibits Na-K-2Cl cotransporter | SLC12A2 | Phase 1 | Healthy Adult Male and Female Volunteers | – |
Heart Failure (1) Healthy Adult Male and Female Volunteers (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.